Skip to content
Peptide research

Cortexin

Also known as Brain Polypeptide Complex
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

A cerebral-cortex polypeptide complex marketed for cognitive support and stroke recovery. Human evidence is moderate at best, mostly older Eastern European trials on stroke recovery and elderly cognition, while pediatric and developmental-delay uses rest on low-confidence data. As a crude tissue extract, it carries a real allergic-reaction risk and a theoretical seizure concern. It is not FDA-approved and is sold as an unregulated research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Note: Cortexin is not a single peptide but a polypeptide complex derived from the cerebral cortex of young cattle and pigs, containing low-molecular-weight polypeptides, with glycine as an excipient. Like Cerebrolysin, it is an organ-specific peptide extract without a single defined sequence.

Unlike the other Khavinson bioregulators sold as dietary supplements, Cortexin is a registered pharmaceutical drug in Russia, approved for injectable use in neurological conditions. It represents one of the most commercially successful and clinically studied products to emerge from Khavinson's peptide bioregulator research program.

Cortexin is primarily administered as an intramuscular injection and is prescribed in Russia for a wide range of neurological conditions including stroke recovery, traumatic brain injury, epilepsy, cognitive impairment, and neurodevelopmental delays in children. A 2021 PLoS ONE study (PMC8279368) compared the neuroprotective action of Cortexin against Cerebrolysin and Actovegin in rat models of acute and chronic brain ischemia, finding comparable neuroprotective efficacy. A 2025 Biomedicines study (PMC12024793) evaluated Cortexin's neurotropic effects on models of mental and physical developmental delay.

Cortexin is distinct from the Cytomaxes supplement line in that it has undergone formal pharmaceutical registration in Russia, has more extensive published research (including in PubMed/PMC-indexed journals), and is administered by injection rather than oral capsules. However, it shares the same fundamental theory of organ-specific peptide bioregulation.

How it works in the body

A polypeptide complex extracted from cerebral cortex containing low-molecular-weight polypeptides, with glycine as an excipient. It provides neurotrophic support by activating BDNF and NGF pathways, enhancing synaptic transmission, reducing excitotoxicity, and promoting neuronal survival under stress conditions.

Research overview

Cortexin has the most extensive published research of any Khavinson neuropeptide product. Key studies include: a 2021 comparative neuroprotection study vs. Cerebrolysin and Actovegin in brain ischemia models (PMC8279368, PLoS ONE), a 2025 study on neurotropic effects in developmental delay models (PMC12024793, Biomedicines), and the 2013 review of neuroprotective peptide bioregulators in elderly patients (PMID 24738258). Cortexin has been studied in pediatric neurology (developmental delays, epilepsy, perinatal CNS damage), adult neurology (stroke, TBI, cognitive impairment), and geriatric neurology (age-related cognitive decline). Russian clinical data includes multiple randomized trials, though few meet Western gold-standard methodology. The drug has been on the Russian pharmaceutical market since 1999.

Who researches Cortexin?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    Not recommended for children outside the pediatric indications on the Russian label; not approved in the US.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Injection site reactions

    Low

    Cortexin (Geropharm) product instruction — adverse reactions section

  • Allergic reactions

    High

    Cortexin (Geropharm) product instruction — contraindications and adverse reactions sections

  • Seizure threshold effects

    Theoretical

    Cortexin (Geropharm) product instruction; analogy to cerebrolysin labelling — no primary seizure data found

Interaction summary(6)

Rated by direction with this peptide

  • Lidocaine (used as a solvent for the powder, especially in children)

    CautionModerate

    Lidocaine is not among the solvents permitted by the label (water for injection, 0.9% NaCl, 0.5% procaine) and dissolving the powder in it is not recommended, particularly in children. Severity reflects the added allergenic and cardiotoxic burden of a local anaesthetic given to a pediatric patient, not a quantified excess-harm dataset.

    Cortexin (Geropharm) product instruction — preparation of solution / pediatric administration

  • Procaine / novocaine (used as a solvent for the powder)

    CautionLow

    Procaine 0.5% is a permitted solvent in the Russian label, but it adds its own local-anaesthetic pharmacology and a well-known allergenic burden at the injection site, so water for injection or 0.9% saline is the safer default.

    Cortexin (Geropharm) product instruction — preparation of solution (permitted solvents: water for injection, 0.9% NaCl, 0.5% procaine)

  • Citicoline

    NeutralLow

    PMID 30874524 is a multicentre observational programme in which all 309 participants received cortexin plus citicoline together, with no control or single-agent comparator arm — it shows the combination was used without reported adverse interaction, but cannot establish synergy or additivity.

    PMID 30874524 (multicentre observational, combination therapy, no control arm)

  • Antiepileptic drugs (carbamazepine, valproate, levetiracetam)

    NeutralTheoretical

    Cortexin carries an adjunctive epilepsy indication in Russia and no pharmacokinetic interaction with antiseizure medication has been demonstrated — but none has been formally studied either, so this is an absence of data rather than a demonstrated absence of interaction. Monitor seizure control if added.

    Cortexin (Geropharm) product instruction — indications; no interaction studies published

  • Other neurotrophic peptide preparations (cerebrolysin, actovegin, Cerebrolysate)

    CautionTheoretical

    Using multiple heterologous animal-brain-derived parenteral hydrolysates together compounds immunogenic/allergic exposure with no evidence of additive benefit. The cited studies are verified head-to-head animal comparisons (rats), not combination studies, so the 'overlapping rather than complementary' reading is an inference from preclinical data only.

    PMID 34260655; PMID 32929929 (rat head-to-head comparisons, not combination studies)

  • Pregnancy and breastfeeding (not a drug interaction — an absolute label use restriction)

    CautionModerate

    Severity reduced from High. Cortexin is contraindicated in pregnancy and breastfeeding should be stopped if it is used, but this rests entirely on absent clinical data rather than any demonstrated fetal or neonatal harm; no teratogenicity or lactation signal has been reported. The restriction is absolute in practice, so it remains actionable — but rating it High implies a demonstrated hazard that does not exist in the record.

    Cortexin (Geropharm) product instruction — pregnancy and lactation section

Known risks(3)

  • Injection site reactions

    Low

    Pain, redness, or swelling at injection site reported in some patients.

  • Allergic reactions

    Potentially severe; very rare

    As an animal-derived protein complex, allergic reactions are possible. Skin testing may be recommended before first injection.

  • Seizure threshold effects

    Moderate

    While Cortexin is used for epilepsy, any neuroactive peptide could theoretically affect seizure threshold. Use under neurological supervision.

Drug interactions(3)

  • Anticonvulsants (phenytoin, carbamazepine, valproate)

    Used concurrently in Russian epilepsy practice; monitor seizure control

  • Anticoagulants (warfarin, DOACs)

    No documented interaction; standard precautions for injectable medications

  • Other neuropeptide preparations (Cerebrolysin, Actovegin)

    Generally not used simultaneously; may be used sequentially in Russian practice

Research & benefits

Evidence base

Evidence Level
Moderate Evidence (registered drug in Russia with published studies)
Total Studies
50
Human Participants
2000

Cortexin is a registered pharmaceutical in Russia with more extensive clinical evidence than typical bioregulators. PMC-indexed studies demonstrate neuroprotective activity comparable to Cerebrolysin in animal models. Russian clinical trials have enrolled hundreds of patients for conditions including stroke, TBI, epilepsy, and cognitive impairment. However, most studies are Russian-origin, and the drug has not undergone FDA or EMA review. Independent Western replication is limited.

Researched for(5)

Rated by confidence in the evidence

  • Neuroprotection in acute and chronic brain ischemia

    Medium

    Supported by two Russian human RCTs and animal studies; not independently replicated outside Russia.

    PMID 24874316; PMID 30335070; PMID 34260655; PMID 32929929

  • Neurotropic effects in developmental delay models

    Low

    Single animal study in developmental-delay models; no human confirmation yet.

    PMID 40299434 (Biomedicines 2025) — animal data only

  • Cognitive improvement in elderly patients

    Medium

    One human RCT in elderly patients, plus uncontrolled studies; not independently replicated.

    PMID 30335070 (RCT); PMID 30874524 (observational, combination); PMID 25403301 (open trial)

  • Stroke recovery and rehabilitation support

    Medium

    One double-blind human trial in acute stroke rehabilitation; not independently replicated.

    PMID 24874316

  • Pediatric neurodevelopmental support

    Low

    A small randomized study in 54 children with developmental dysphasia reported improvements against an untreated control group. Evidence remains limited.

    PMID 31851172: randomized developmental-dysphasia study in 54 children; PMID 40299434: animal study.

Benefits(5)

  • Neuroprotection in acute and chronic brain ischemia

    PMC8279368 (PLoS ONE 2021, rat models, Cortexin vs. Cerebrolysin vs. Actovegin)

  • Neurotropic effects in developmental delay models

    PMC12024793 (Biomedicines 2025, rat models)

  • Cognitive improvement in elderly patients

    PMID 24738258 (neuroprotective peptide review); multiple Russian clinical trials

  • Stroke recovery and rehabilitation support

    Russian Phase III/IV clinical trials; prescribed use in Russian neurology practice

  • Pediatric neurodevelopmental support

    Russian pediatric neurology clinical studies

Key studies(3)

  1. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats

    Preclinical comparative studyRat modelsAcute and chronic ischemia protocols

    Kurkin DV, Bakulin DA, Morkovin EI, et al.

    PLoS ONE

    2021

    First comparative study of three major neuroprotective agents. Cortexin showed neuroprotective activity comparable to Cerebrolysin in both acute and chronic brain ischemia models, with improvements in neurological deficit scores and histological outcomes.

  2. Kurkin DV, Bakulin DA, Morkovin EI, et al.

    Biomedicines

    2025

    Cortexin demonstrated neurotropic effects in rat models of mental and physical developmental delays, supporting its use in pediatric neurology applications.

  3. Umnov RS, Lin'kova NS, Khavinson VKh.

    Advances in Gerontology

    2013

    Review of neuroprotective peptide groups including Cortexin, describing clinical application in elderly patients and molecular mechanisms of neuroprotection.

Regulation & availability

Why researchers look at it

Cortexin is the most clinically validated Khavinson neuropeptide, registered as a drug in Russia with extensive published research. Its neuroprotective properties have been compared favorably to Cerebrolysin in published studies.

Estimated cost
$50-150/course (10-20 day IM injection course; available in Russia, some international pharmacies)
FDA status
Not FDA-approved; registered pharmaceutical in Russia since 1999
WADA status
Not listed on WADA Prohibited List; not evaluated by WADA
Prescribability
Registered drug in Russia; available by prescription in CIS countries; not approved in USA/EU
Availability
Available by prescription in Russia and CIS countries as an injectable pharmaceutical. Not available through conventional channels in the USA or EU. Not FDA/EMA-approved.

International status

  • EU

    Not approved

  • US

    Not approved; not available

  • CIS

    Approved in multiple CIS countries

  • Russia

    Registered pharmaceutical (approved for neurological conditions)

  • Worldwide

    Approved primarily in Russia and CIS states

Regulatory timeline(6)

  1. 1990s
    Developed at St. Petersburg Institute of Bioregulation and Gerontology
  2. 1999
    Registered as pharmaceutical drug in Russia
  3. 2000s
    Widely prescribed in Russian neurology practice
  4. 2013
    Neuroprotective peptide review published (PMID 24738258)
  5. 2021
    Comparative study vs. Cerebrolysin published in PLoS ONE (PMC8279368)
  6. 2025
    Neurotropic effects study published in Biomedicines (PMC12024793)

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

How is Cortexin different from other Khavinson bioregulators?

Cortexin is a registered pharmaceutical drug in Russia, not just a dietary supplement. It is administered by intramuscular injection, has undergone formal clinical trials for drug registration, and has significantly more published research than supplement-class bioregulators. It is prescribed by neurologists for specific conditions.

What conditions is Cortexin approved for in Russia?

Cortexin is approved for cerebrovascular diseases (stroke, chronic cerebral ischemia), traumatic brain injury, epilepsy, cognitive impairment in various etiologies, encephalopathy, and certain pediatric neurological conditions including perinatal CNS damage and developmental delays.

How is Cortexin administered?

Cortexin is given by intramuscular injection.

Is Cortexin similar to Cerebrolysin?

Both are neuropeptide complexes used in neurological conditions. Cerebrolysin is derived from porcine brain tissue and is more widely known internationally. The 2021 PLoS ONE study showed comparable neuroprotective efficacy between the two in animal models.